The identification of NF-κB as a key player in the pathogenesis of inflammation suggests that NF-κB-targeted therapeutics might be effective in treating diseases like rheumatoid arthritis (RA), which is a well-known disease where inflammatory response is causing the primary damage [8]. This evidence concerns the gene NFKB1 and rheumatoid arthritis.